MLchartDataset catalogue

Anti-M-CSF monoclonal antibody MCS110

Term · Oncology and biomedicine · MLC-T-ONC-010879

A humanized monoclonal antibody directed against macrophage colony-stimulating factor (M-CSF) with potential anti-osteolytic activity. Anti-M-CSF monoclonal antibody MCS110 binds to M-CSF and blocks M-CSF-mediated signaling through the M-CSF receptor CD116 expressed on osteoclasts, which may result in inhibition of M-CSF-induced osteoclast differentiation and so osteoclastic bone resorption. Osteoclasts are derived through the fusion of cells of the monocyte/macrophage lineage. Osteoblasts and stromal cells may react to bone metastases by producing M-CSF and its osteoclastogenic cofactor RANKL (receptor activator of NF-kappaB ligand).

Table 1. Record
IdentifierMLC-T-ONC-010879
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010879",
  "term": "Anti-M-CSF monoclonal antibody MCS110",
  "field": "Oncology and biomedicine",
  "definition": "A humanized monoclonal antibody directed against macrophage colony-stimulating factor (M-CSF) with potential anti-osteolytic activity. Anti-M-CSF monoclonal antibody MCS110 binds to M-CSF and blocks M-CSF-mediated signaling through the M-CSF receptor CD116 expressed on osteoclasts, which may result in inhibition of M-CSF-induced osteoclast differentiation and so osteoclastic bone resorption. Osteoclasts are derived through the fusion of cells of the monocyte/macrophage lineage. Osteoblasts and stromal cells may react to bone metastases by producing M-CSF and its osteoclastogenic cofactor RANKL (receptor activator of NF-kappaB ligand).",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-m-csf-monoclonal-antibody-mcs110/"
}

Record 1,997 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.